Objective: To investigate the human leukocyte antigen (HLA) association with anti-synthetase syndrome (ASSD). Methods: We conducted the largest immunogenetic HLA-DRB1 and HLA-B study to date in a homogeneous cohort of 168 Caucasian patients with ASSD and 486 ethnically matched healthy controls by sequencing-based-typing. Results: A statistically significant increase of HLA-DRB1*03:01 and HLA-B*08:01 alleles in patients with ASSD compared to healthy controls was disclosed (26.2% versus 12.2%, P = 1.56E–09, odds ratio–OR [95% confidence interval–CI] = 2.54 [1.84–3.50] and 21.4% versus 5.5%, P = 18.95E–18, OR [95% CI] = 4.73 [3.18–7.05]; respectively). Additionally, HLA-DRB1*07:01 allele was significantly decreased in patients with ASSD compared to controls (9.2% versus 17.5%, P = 0.0003, OR [95% CI] = 0.48 [0.31–0.72]). Moreover, a statistically significant increase of HLA-DRB1*03:01 allele in anti-Jo-1 positive compared to anti-Jo-1 negative patients with ASSD was observed (31.8% versus 15.5%, P = 0.001, OR [95% CI] = 2.54 [1.39–4.81]). Similar findings were observed when HLA carrier frequencies were assessed. The HLA-DRB1*03:01 association with anti-Jo-1 was unrelated to smoking history. No HLA differences in patients with ASSD stratified according to the presence/absence of the most representative non-anti-Jo-1 anti-synthetase autoantibodies (anti-PL-12 and anti-PL-7), arthritis, myositis or interstitial lung disease were observed. Conclusions: Our results support the association of the HLA complex with the susceptibility to ASSD.

HLA association with the susceptibility to anti-synthetase syndrome

Cavagna L.;
2021-01-01

Abstract

Objective: To investigate the human leukocyte antigen (HLA) association with anti-synthetase syndrome (ASSD). Methods: We conducted the largest immunogenetic HLA-DRB1 and HLA-B study to date in a homogeneous cohort of 168 Caucasian patients with ASSD and 486 ethnically matched healthy controls by sequencing-based-typing. Results: A statistically significant increase of HLA-DRB1*03:01 and HLA-B*08:01 alleles in patients with ASSD compared to healthy controls was disclosed (26.2% versus 12.2%, P = 1.56E–09, odds ratio–OR [95% confidence interval–CI] = 2.54 [1.84–3.50] and 21.4% versus 5.5%, P = 18.95E–18, OR [95% CI] = 4.73 [3.18–7.05]; respectively). Additionally, HLA-DRB1*07:01 allele was significantly decreased in patients with ASSD compared to controls (9.2% versus 17.5%, P = 0.0003, OR [95% CI] = 0.48 [0.31–0.72]). Moreover, a statistically significant increase of HLA-DRB1*03:01 allele in anti-Jo-1 positive compared to anti-Jo-1 negative patients with ASSD was observed (31.8% versus 15.5%, P = 0.001, OR [95% CI] = 2.54 [1.39–4.81]). Similar findings were observed when HLA carrier frequencies were assessed. The HLA-DRB1*03:01 association with anti-Jo-1 was unrelated to smoking history. No HLA differences in patients with ASSD stratified according to the presence/absence of the most representative non-anti-Jo-1 anti-synthetase autoantibodies (anti-PL-12 and anti-PL-7), arthritis, myositis or interstitial lung disease were observed. Conclusions: Our results support the association of the HLA complex with the susceptibility to ASSD.
2021
The Rheumatology category covers resources on clinical, laboratory, and therapeutic research in all aspects of rheumatology including arthritis and rheumatism.
Esperti anonimi
Inglese
Internazionale
ELETTRONICO
88
3
105115
Anti-Jo-1 antibodies; Anti-synthetase syndrome; HLA; HLA-B*08:01; HLA-DRB1*03:01; HLA-DRB1*07:01
https://pdf.sciencedirectassets.com/272233/1-s2.0-S1297319X21X00048/1-s2.0-S1297319X20302220/main.pdf?X-Amz-Security-Token=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&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20210512T094657Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTYUPD4M4TP/20210512/us-east-1/s3/aws4_request&X-Amz-Signature=08f758960c1a91358a02d2dfc4e3e8b3dd6a18c94d88e83083e1dd57f0921bc7&hash=6734ccf5413040ec38b70e551882773e195b0ed2fc7f15fa64e98a646a93bb27&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S1297319X20302220&tid=spdf-b54295bc-2f8f-41ad-a91a-4322f2835c67&sid=fea12e6b6143e141db6a2e8403dcb11806bagxrqb&type=client
38
info:eu-repo/semantics/article
262
Remuzgo-Martinez, S.; Atienza-Mateo, B.; Ocejo-Vinyals, J. G.; Pulito-Cueto, V.; Prieto-Pena, D.; Genre, F.; Marquez, A.; Llorca, J.; Mora Cuesta, V. ...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1433574
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 16
social impact